| pubmed-article:17896922 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17896922 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:17896922 | lifeskim:mentions | umls-concept:C0005839 | lld:lifeskim |
| pubmed-article:17896922 | lifeskim:mentions | umls-concept:C0302600 | lld:lifeskim |
| pubmed-article:17896922 | lifeskim:mentions | umls-concept:C0026046 | lld:lifeskim |
| pubmed-article:17896922 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:17896922 | lifeskim:mentions | umls-concept:C0920425 | lld:lifeskim |
| pubmed-article:17896922 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17896922 | pubmed:dateCreated | 2007-9-27 | lld:pubmed |
| pubmed-article:17896922 | pubmed:abstractText | Anticancer agents that interfere with tubulin functions are widely used in the clinic and have a broad spectrum of activity against both haematological malignancies and solid tumours. These Microtubule-Targeting Agents (MTAs), such as the taxanes and Vinca alkaloids, bind to the beta subunit of alpha/beta tubulin and disrupt microtubule dynamics in tumour cells, ultimately leading to mitotic block and subsequent cell death. Recently, MTAs have received considerable interest as potential tumour-selective anti-angiogenic and vascular-disrupting agents. Angiogenesis is a keystone of tumour progression and metastasis and targeting the formation of new blood vessels within the tumour is therefore regarded as a promising strategy for cancer therapy. In this regard, conventional MTAs can be given on daily schedules at non-toxic doses (metronomic dosing) to disturb tumour angiogenesis. Some MTAs can also act as vascular-disrupting agents. After briefly reviewing the classical mechanisms involved in the anti-tumour action of MTAs, we will focus on the latest studies investigating the molecular and cellular processes underlying the anti-angiogenic and the vascular-disrupting properties of these agents. We will also review and discuss the potential clinical development and the limitations of MTAs used as tumour-specific anti-vascular molecules. | lld:pubmed |
| pubmed-article:17896922 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17896922 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17896922 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17896922 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17896922 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17896922 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17896922 | pubmed:issn | 1873-5576 | lld:pubmed |
| pubmed-article:17896922 | pubmed:author | pubmed-author:AndréNicolasN | lld:pubmed |
| pubmed-article:17896922 | pubmed:author | pubmed-author:BraguerDianeD | lld:pubmed |
| pubmed-article:17896922 | pubmed:author | pubmed-author:PasquierEddyE | lld:pubmed |
| pubmed-article:17896922 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17896922 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:17896922 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17896922 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17896922 | pubmed:pagination | 566-81 | lld:pubmed |
| pubmed-article:17896922 | pubmed:dateRevised | 2008-9-9 | lld:pubmed |
| pubmed-article:17896922 | pubmed:meshHeading | pubmed-meshheading:17896922... | lld:pubmed |
| pubmed-article:17896922 | pubmed:meshHeading | pubmed-meshheading:17896922... | lld:pubmed |
| pubmed-article:17896922 | pubmed:meshHeading | pubmed-meshheading:17896922... | lld:pubmed |
| pubmed-article:17896922 | pubmed:meshHeading | pubmed-meshheading:17896922... | lld:pubmed |
| pubmed-article:17896922 | pubmed:meshHeading | pubmed-meshheading:17896922... | lld:pubmed |
| pubmed-article:17896922 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17896922 | pubmed:articleTitle | Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. | lld:pubmed |
| pubmed-article:17896922 | pubmed:affiliation | FRE-CNRS 2737, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), University of Aix-Marseille, 27 bd Jean Moulin, 13005 Marseille, France. | lld:pubmed |
| pubmed-article:17896922 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17896922 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:17896922 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17896922 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17896922 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17896922 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17896922 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17896922 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17896922 | lld:pubmed |
